Hikma Pharmaceuticals PLC (LSE:HIK) - Share price


Stock Report

Hikma Pharmaceuticals PLC HIK

Last Price
GBX2,467.00

Day Change
20.00|0.82%

As of 14/06/2021
12:51:53 BST | GBX
Minimum 15 Minutes Delay.

Last Close2,447.00p
Day Range2,451.00 - 2,472.00
Mkt Cap5.66Bil
52-Wk Range2,086.49 - 2,768.00
Yield %1.50
ISINGB00B0LCW083
Volume30,293
P/E19.05
P/S2.51
P/CF12.65

Share Price

Total Returns 11/06/2021

 Chg (%)  
More ...
Hikma Pharmaceuticals PLC6.35 
FTSE 100 TR GBP3.00
 
Financials
201820192020
More ...
Income Statement
Turnover2,070.002,207.002,341.00
Operating Profit371.00449.00560.00
Net Profit285.00487.00430.00
Reported EPS1.172.001.81
Balance Sheet
Current Assets1,668.001,848.001,922.00
Non Current Assets1,829.002,082.002,213.00
Total Assets3,497.003,930.004,135.00
Current Liabilities893.001,471.001,028.00
Total Liabilities---
Total Equity1,697.002,129.002,148.00
Cash Flow
Operating Cash Flow493.00580.00525.00
Net Change in Cash56.00166.00-117.00

Regulatory News

DateAuthor Headline
12/12/2019James Gard Britain Needs More Big Brands, says Nick Train
Something's wrong if only five UK companies make it on the list of top 100 global brands, says fund manager Nick Train
26/09/2019James Gard Job Curtis Backs St James's Place
FTSE 100 wealth manager, which has come under fire for adviser perks recently, is the 20th largest holding in the Silver-rated City of London Investment Trust
28/05/2019James Gard Galliford Try Rejects Bovis Approach
Talks with FTSE 250 housebuilder Bovis to buy Galliford's housebuilding arm have broken down
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
17/05/2021Transfer inMr. Mazen Samih Taleb Darwazah0.0012,0420.00
17/03/2021PurchaseMs. Nina Henderson2,203.001,60035,248.00
12/03/2021Transfer inMr. Mazen Samih Taleb Darwazah0.0042,5720.00
12/03/2021Transfer inMr. Said Darwazah0.0061,6660.00

Company Profile

Founded in the Middle East with headquarters in London, Hikma manufactures generic and in-licensed pharmaceuticals. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.

Sector

Drug Manufacturers - Specialty & Generic

Index

FTSE 100 , FTSE 350 , FTSE All Share

Next Event 06/08/2021

Half-Yearly Results
Ratios
Comp
More ...
PER (E)19.14
Div Yld (E)1.50
PEG (E)0.00
ROCE19.76
Op Mrgn0.24
EPS Grwth-0.09
Dividends
PreviousLatest
More ...
Record Date21/08/2019/03/21
Ex-Div20/08/2018/03/21
Paid21/09/2026/04/21
Amnt12.0024.70
Directors
More ...
Non-Executive DirectorDr. Pamela Josephine Kirby
Executive Director, Vice ChairmanMr. Mazen Samih Taleb Darwazah
Non-Executive DirectorMr. Mohammed Ali Khaldoun S Al-Husry
Non-Executive DirectorMr. Douglas Michael Hurt
Executive Director, ChairmanMr. Said Darwazah
Executive Director, Chief Executive OfficerMr. Sigurdur Olafsson
Non-Executive DirectorMs. Nina Henderson
Non-Executive Director, Senior Independent DirectorMr. Patrick Butler
Non-Executive DirectorMr. John Julius Castellani
Non-Executive DirectorMs. Cynthia L. Schwalm
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.